3086 related articles for article (PubMed ID: 6334137)
1. Intralesional injection of interleukin-2-expanded autologous lymphocytes in melanoma and breast cancer patients: a pilot study.
Adler A; Stein JA; Kedar E; Naor D; Weiss DW
J Biol Response Mod; 1984 Oct; 3(5):491-500. PubMed ID: 6334137
[TBL] [Abstract][Full Text] [Related]
2. [Autologous tumor specific immunotherapy of refractory cancers with ex vivo-generated T cells stimulated by autologous tumor cell].
Toh U; Yamana H; Kido K; Mine T; Fujii T; Horiuchi H; Sasatomi T; Ishibashi N; Yutani S; Fujita H; Shirouzu K
Gan To Kagaku Ryoho; 2003 Oct; 30(11):1566-70. PubMed ID: 14619465
[TBL] [Abstract][Full Text] [Related]
3. Cytolysis of mammary tumor targets by resting, interleukin-2 stimulated and in vitro cultured peripheral blood lymphocytes from breast cancer patients.
Brenner BG; McCrea EL; Margolese RG
Anticancer Res; 1988; 8(4):653-8. PubMed ID: 3263077
[TBL] [Abstract][Full Text] [Related]
4. Clinical observations on adoptive immunotherapy with vaccine-primed T-lymphocytes secondarily sensitized to tumor in vitro.
Chang AE; Yoshizawa H; Sakai K; Cameron MJ; Sondak VK; Shu S
Cancer Res; 1993 Mar; 53(5):1043-50. PubMed ID: 8439951
[TBL] [Abstract][Full Text] [Related]
5. Limiting dilution analysis of the frequency of human T cells and large granular lymphocytes proliferating in response to interleukin 2. I. The effect of lectin on the proliferative frequency and cytotoxic activity of cultured lymphoid cells.
Vose BM; Bonnard GD
J Immunol; 1983 Feb; 130(2):687-93. PubMed ID: 6600251
[TBL] [Abstract][Full Text] [Related]
6. [Basic and clinical study of adoptive immunotherapy using cytotoxic T lymphocyte (CTL) against cancers].
Kitsukawa K
Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-2):1448-54. PubMed ID: 2543306
[TBL] [Abstract][Full Text] [Related]
7. Preliminary experiences of intralesional immunotherapy in cutaneous metastatic melanoma.
Ridolfi L; Ridolfi R
Hepatogastroenterology; 2002; 49(44):335-9. PubMed ID: 11995445
[TBL] [Abstract][Full Text] [Related]
8. Interleukin 15 induction of lymphokine-activated killer cell function against autologous tumor cells in melanoma patient lymphocytes by a CD18-dependent, perforin-related mechanism.
Gamero AM; Ussery D; Reintgen DS; Puleo CA; Djeu JY
Cancer Res; 1995 Nov; 55(21):4988-94. PubMed ID: 7585540
[TBL] [Abstract][Full Text] [Related]
9. IL-2 gene-transduced human HLA-A2 melanoma cells can generate a specific antitumor cytotoxic T-lymphocyte response.
Guarini A; Gansbacher B; Cronin K; Fierro MT; Foa R
Cytokines Mol Ther; 1995 Mar; 1(1):57-64. PubMed ID: 9384664
[TBL] [Abstract][Full Text] [Related]
10. Vaccination with IL-12 gene-modified autologous melanoma cells: preclinical results and a first clinical phase I study.
Sun Y; Jurgovsky K; Möller P; Alijagic S; Dorbic T; Georgieva J; Wittig B; Schadendorf D
Gene Ther; 1998 Apr; 5(4):481-90. PubMed ID: 9614572
[TBL] [Abstract][Full Text] [Related]
11. Dendritoma vaccination combined with low dose interleukin-2 in metastatic melanoma patients induced immunological and clinical responses.
Wei Y; Sticca RP; Holmes LM; Burgin KE; Li J; Williamson J; Evans L; Smith SJ; Stephenson JJ; Wagner TE
Int J Oncol; 2006 Mar; 28(3):585-93. PubMed ID: 16465362
[TBL] [Abstract][Full Text] [Related]
12. Intra-lymphatic administration of interleukin-2 (IL-2) in cancer patients: a pilot study.
Pizza G; Viza D; De Vinci C; Vich i Pascuchi JM; Busutti L; Bergami T
Lymphokine Res; 1988; 7(1):45-8. PubMed ID: 3283468
[TBL] [Abstract][Full Text] [Related]
13. IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: a phase I/II trial.
Burns LJ; Weisdorf DJ; DeFor TE; Vesole DH; Repka TL; Blazar BR; Burger SR; Panoskaltsis-Mortari A; Keever-Taylor CA; Zhang MJ; Miller JS
Bone Marrow Transplant; 2003 Jul; 32(2):177-86. PubMed ID: 12838283
[TBL] [Abstract][Full Text] [Related]
14. Minimally cultured or selected autologous tumor-infiltrating lymphocytes after a lympho-depleting chemotherapy regimen in metastatic melanoma patients.
Besser MJ; Shapira-Frommer R; Treves AJ; Zippel D; Itzhaki O; Schallmach E; Kubi A; Shalmon B; Hardan I; Catane R; Segal E; Markel G; Apter S; Nun AB; Kuchuk I; Shimoni A; Nagler A; Schachter J
J Immunother; 2009 May; 32(4):415-23. PubMed ID: 19342963
[TBL] [Abstract][Full Text] [Related]
15. The role of interleukin-2, interleukin-12, and dendritic cells in cancer therapy.
Lotze MT; Hellerstedt B; Stolinski L; Tueting T; Wilson C; Kinzler D; Vu H; Rubin JT; Storkus W; Tahara H; Elder E; Whiteside T
Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S109-14. PubMed ID: 9457405
[TBL] [Abstract][Full Text] [Related]
16. IL-2 enhances standard IFNgamma/LPS activation of macrophage cytotoxicity to human ovarian carcinoma in vitro: a potential for adoptive cellular immunotherapy.
Han X; Wilbanks GD; Devaja O; Ruperelia V; Raju KS
Gynecol Oncol; 1999 Nov; 75(2):198-210. PubMed ID: 10525372
[TBL] [Abstract][Full Text] [Related]
17. Peripheral burst of tumor-specific cytotoxic T lymphocytes and infiltration of metastatic lesions by memory CD8+ T cells in melanoma patients receiving interleukin 12.
Mortarini R; Borri A; Tragni G; Bersani I; Vegetti C; Bajetta E; Pilotti S; Cerundolo V; Anichini A
Cancer Res; 2000 Jul; 60(13):3559-68. PubMed ID: 10910069
[TBL] [Abstract][Full Text] [Related]
18. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report.
Rosenberg SA; Packard BS; Aebersold PM; Solomon D; Topalian SL; Toy ST; Simon P; Lotze MT; Yang JC; Seipp CA
N Engl J Med; 1988 Dec; 319(25):1676-80. PubMed ID: 3264384
[TBL] [Abstract][Full Text] [Related]
19. Low dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer cell activity.
Miller JS; Tessmer-Tuck J; Pierson BA; Weisdorf D; McGlave P; Blazar BR; Katsanis E; Verfaillie C; Lebkowski J; Radford J; Burns LJ
Biol Blood Marrow Transplant; 1997 Apr; 3(1):34-44. PubMed ID: 9209739
[TBL] [Abstract][Full Text] [Related]
20. Increased non-major histocompatibility complex-restricted lytic activity in melanoma patients vaccinated with cytokine gene-transfected autologous tumor cells.
Möller P; Möller H; Sun Y; Dorbic T; Henz BM; Wittig B; Schadendorf D
Cancer Gene Ther; 2000 Jul; 7(7):976-84. PubMed ID: 10917199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
